News | November 06, 2024
Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Subscribe To Our Newsletter & Stay Updated
